Kancherla joined Arrien Pharmaceuticals as SAB Member on September 2014. He brings extensive experience in building, and leading clinical Oncology groups and managing Clinical trials programs from First-In-Human trials to approvals across multiple cancer therapeutics. Dr. Kancherla currently serving as Managing Partner for Hudson Valley Hematology/Oncology Associates, Chairman of Hematology/Oncology at St. Francis Hospital and Director of research at Vassar Brothers Medical Center. Dr. Kancherla was most recently the Director of the Autologous Stem Cell and Transplant Program at New York Medical College, where he performed a few hundred stem cell transplants. Dr. Kancherla was also served as Assistant Professor at New York Medical College.

Dr. Kancherla competed his Residency and Fellowship in Hematology and Oncology from State University of New York at Brooklyn and New York Medical College. He received his Bachelor of Medicine degree from Rangaraya Medical College of University of Health Science from India in 1982. Dr. Kancherla published more than 30 publications in Clinical Research both in Hematology and Oncology disciplines.

Hari is a founder of Arrien Pharmaceuticals, serves as Chief Scientific Officer and SAB Member of the Company. Hari developed the empirical-driven FIELDS technology, successfully translated the FIELDS in to early discovery pipeline of targeted therapeutics development for Cancer, Autoimmune and CNS/Neurodegenerative diseases. He is currently serving as Associate Prof. at TGen supporting drug discovery programs for cancer immunotherapeutics. He was Asst. Prof./Chief Scientist at the Center for Investigational Therapeutics (CIT) of The Huntsman Cancer Institute (HCI) and School of Medicine of University of Utah. His presence at HCI lead to the discovery of two agents (HCI-2577/SP-2577, HCI-2084/TP-0903) currently in Phase 1 clinical trials. From 2006-2009, Hari was Chief Scientist at SuperGen, Inc., (now Astex/Otsuka Pharmaceuticals). From 2003-2006 he was a Director of Medicinal Chemistry for early discovery/development activities and was key in creating three clinical agents; MP-470/Amuvatinib, SGI-1776 and SGI-110/Guadecitabine, several pre-clinical candidates, CLIMB technology and co-founded Montigen Pharmaceuticals with an initial Series B of 5 million. In year 2006 Montigen was acquired by SuperGen for 40 million where Hari played a key role in bringing science/technology in this deal transaction.

He is an author of more than 70 publications, presentations, and an inventor of several issued/published US/WO patents. Hari received Ph.D. and M. Pharm degrees in Medicinal Chemistry from Institute of Chemical Technology (formally UDCT) of University of Mumbai and University of Karnatak in India. He completed his Postdoctoral training in Organic Chemistry from University of Sunderland in England and Medicinal Chemistry from University of Arizona Cancer Center with Prof. Laurence H. Hurley.